These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9051704)

  • 1. Cholesterol synthesis inhibitors do not reduce Lp(a) levels in normocholesterolemic patients.
    Pazzucconi F; Franceschini G; Gianfranceschi G; Campagnoli G; Sirtori CR
    Pharmacol Res; 1996; 34(3-4):131-3. PubMed ID: 9051704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
    Branchi A; Rovellini A; Fiorenza AM; Sommariva D
    Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.
    Kostner GM; Gavish D; Leopold B; Bolzano K; Weintraub MS; Breslow JL
    Circulation; 1989 Nov; 80(5):1313-9. PubMed ID: 2530005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin.
    Chao Y; Chen JS; Hunt VM; Kuron GW; Karkas JD; Liou R; Alberts AW
    Eur J Clin Pharmacol; 1991; 40 Suppl 1():S11-4. PubMed ID: 2044637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of 2 cholesterol synthesis inhibitors (simvastatin and pravastatin)].
    Golay A; Lehmann T; James R; Pometta D
    Schweiz Med Wochenschr; 1993 Aug; 123(33):1553-8. PubMed ID: 8372340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin.
    Del Puppo M; Rauli S; Galli Kienle M
    Lipids; 1995 Nov; 30(11):1057-61. PubMed ID: 8569435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones.
    Ide H; Fujiya S; Aanuma Y; Agishi Y
    Clin Ther; 1990; 12(5):410-20. PubMed ID: 2268863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of simvastatin and pravastatin on endothelium-dependent relaxation in hypercholesterolemic rabbits.
    Jorge PA; Ozaki MR; Metze K
    Exp Toxicol Pathol; 1994 Dec; 46(6):465-9. PubMed ID: 7703678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin.
    De Vries AC; Vermeer MA; Bredman JJ; Bär PR; Cohen LH
    Exp Eye Res; 1993 Apr; 56(4):393-9. PubMed ID: 8500554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin.
    Slunga L; Johnson O; Dahlén GH
    Eur J Clin Pharmacol; 1992; 43(4):369-73. PubMed ID: 1451715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies.
    Keidar S; Aviram M; Maor I; Oiknine J; Brook JG
    Br J Clin Pharmacol; 1994 Dec; 38(6):513-9. PubMed ID: 7888289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long term treatment of moderate to severe hypercholesterolemia with low dose statin. Comparison of simvastatin and pravastatin].
    Spagnolli W; Ramponi C; Focher C; Dal Piaz A; Torboli P; Miori R; De Venuto G
    Recenti Prog Med; 1996 Nov; 87(11):538-42. PubMed ID: 9122535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of simvastatin on blood levels of lipoprotein (a)].
    Galetta F; Sampietro T; Basta G; Giannasi G; Bionda A
    Minerva Med; 1995; 86(7-8):299-303. PubMed ID: 7478073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of simvastatin on Lp(a) concentrations.
    Haffner S; Orchard T; Stein E; Schmidt D; LaBelle P
    Clin Cardiol; 1995 May; 18(5):261-7. PubMed ID: 7628131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers.
    Malmendier CL; Lontie JF; Delcroix C; Magot T
    Atherosclerosis; 1989 Dec; 80(2):101-9. PubMed ID: 2610723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors.
    Sirtori CR
    Pharmacol Ther; 1993 Dec; 60(3):431-59. PubMed ID: 8073070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HMG-CoA-reductase inhibitors: a new principle in the treatment of hypercholesterolemia].
    Saxenhofer H; Weidmann P
    Ther Umsch; 1990 Jun; 47(6):509-13. PubMed ID: 2375007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of clinical trials comparing HMG-CoA reductase inhibitors.
    Illingworth DR; Tobert JA
    Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.